RCM
LXEO icon

RA Capital Management’s Lexeo Therapeutics LXEO Stock Holding History

RA Capital Management’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$28.7M Hold
5,000,000
– – 0.3% 47
2025
Q4 		$49.6M Buy
+5,000,000
New +$45.6M 0.51% 35
2025
Q2 		– Sell
-546,554
Closed -$1.9M – 79
2025
Q1 		$1.9M Hold
546,554
– – 0.03% 83
2024
Q4 		$3.6M Hold
546,554
– – 0.05% 85
2024
Q3 		$4.94M Sell
546,554
-126,158
-19% -$1.5M 0.06% 73
2024
Q2 		$10.8M Buy
672,712
+11,774
+2% +$171K 0.14% 66
2024
Q1 		$10.4M Buy
+660,938
New +$10.3M 0.13% 70

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RA Capital Management's LXEO Position: Q1 2026 in Review

RA Capital Management held its Lexeo Therapeutics (LXEO) position steady in Q1 2026 at 5,000,000 shares worth $28.7M. The position accounts for 0.3% of the portfolio, ranked #47.

RA Capital Management first reported a position in LXEO in Q1 2024 and has held it in 7 quarters since. The position peaked at $49.6M in Q4 2025. 139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

  • RA Capital Management held 5,000,000 shares of Lexeo Therapeutics worth $28.7M as of Q1 2026.
  • RA Capital Management left its Lexeo Therapeutics share count unchanged in Q1 2026.
  • Lexeo Therapeutics made up 0.3% of RA Capital Management's portfolio in Q1 2026, its #47 holding.
  • RA Capital Management first reported a position in Lexeo Therapeutics in Q1 2024 and has held it in 7 quarters since.
  • RA Capital Management's Lexeo Therapeutics position peaked at $49.6M in Q4 2025.
  • 139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on RA Capital Management's 13F filing for Q1 2026, filed 15 May 2026.